Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 30;23(7):3817.
doi: 10.3390/ijms23073817.

Recent and Ongoing Research into Metastatic Osteosarcoma Treatments

Michael A Harris  1 , Christine J Hawkins  1
Affiliations
Review

Recent and Ongoing Research into Metastatic Osteosarcoma Treatments

Michael A Harris et al. Int J Mol Sci. .

Abstract

The survival rate for metastatic osteosarcoma has not improved for several decades, since the introduction and refinement of chemotherapy as a treatment in addition to surgery. Over two thirds of metastatic osteosarcoma patients, many of whom are children or adolescents, fail to exhibit durable responses and succumb to their disease. Concerted efforts have been made to increase survival rates through identification of candidate therapies via animal studies and early phase trials of novel treatments, but unfortunately, this work has produced negligible improvements to the survival rate for metastatic osteosarcoma patients. This review summarizes data from clinical trials of metastatic osteosarcoma therapies as well as pre-clinical studies that report efficacy of novel drugs against metastatic osteosarcoma in vivo. Considerations regarding the design of animal studies and clinical trials to improve survival outcomes for metastatic osteosarcoma patients are also discussed.

Keywords: animal models; cancer; immunotherapy; metastases; metastasis; metastatic; osteosarcoma; progression free survival; sarcoma; tyrosine kinase inhibitors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Therapies and their mechanism of action currently being evaluated to treat metastatic osteosarcoma in clinical trials.
See this image and copyright information in PMC

References

    1. Gianferante D.M., Mirabello L., Savage S.A. Germline and somatic genetics of osteosarcoma—Connecting aetiology, biology and therapy. Nat. Rev. Endocrinol. 2017;13:480–491. doi: 10.1038/nrendo.2017.16. - DOI - PubMed
    1. Abarrategi A., Tornin J., Martinez-Cruzado L., Hamilton A., Martinez-Campos E., Rodrigo J.P., Gonzalez M.V., Baldini N., Garcia-Castro J., Rodriguez R. Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. Stem Cells Int. 2016;2016:3631764. doi: 10.1155/2016/3631764. - DOI - PMC - PubMed
    1. Walia M.K., Castillo-Tandazo W., Mutsaers A.J., Martin T.J., Walkley C.R. Murine models of osteosarcoma: A piece of the translational puzzle. J. Cell Biochem. 2018;119:4241–4250. doi: 10.1002/jcb.26601. - DOI - PubMed
    1. Mirabello L., Troisi R.J., Savage S.A. Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115:1531–1543. doi: 10.1002/cncr.24121. - DOI - PMC - PubMed
    1. Coventry M.B., Dahlin D.C. Osteogenic sarcoma; a critical analysis of 430 cases. J. Bone Joint. Surg. Am. 1957;39:741–758. doi: 10.2106/00004623-195739040-00002. - DOI - PubMed